This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare. This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

## **Revision of PRECAUTIONS**

## Nirmatrelvir/ritonavir

April 8, 2025

## **Therapeutic category**

Anti-virus agents

Non-proprietary name

Nirmatrelvir/ritonavir

Safety measure PRECAUTIONS should be revised.

Revised language is underlined.

	Revised language is underlined.
Current	Revision
2. CONTRAINDICATIONS (This drug is contraindicated to the following	2. CONTRAINDICATIONS (This drug is contraindicated to the following
patients.)	patients.)
Patients receiving the following drugs: Eletriptan hydrobromide,	Patients receiving the following drugs: Eletriptan hydrobromide,
azelnidipine, olmesartan medoxomil/azelnidipine, eplerenone,	azelnidipine, olmesartan medoxomil/azelnidipine, eplerenone,
amiodarone hydrochloride, bepridil hydrochloride hydrate,	amiodarone hydrochloride, bepridil hydrochloride hydrate,
flecainide acetate, propafenone hydrochloride, quinidine sulfate	flecainide acetate, propafenone hydrochloride, quinidine sulfate
hydrate, rivaroxaban, ticagrelor, anamorelin hydrochloride, rifabutin,	hydrate, rivaroxaban, ticagrelor, anamorelin hydrochloride, rifabutin,
blonanserin, lurasidone hydrochloride, pimozide, suvorexant,	blonanserin, lurasidone hydrochloride, pimozide, suvorexant,
ergotamine tartrate/anhydrous caffeine/isopropylantipyrine,	ergotamine tartrate/anhydrous caffeine/isopropylantipyrine,
ergometrine maleate, dihydroergotamine mesilate,	ergometrine maleate, dihydroergotamine mesilate,
methylergometrine maleate, finerenone, ivabradine hydrochloride,	methylergometrine maleate, finerenone, ivabradine hydrochloride,
sildenafil citrate (Revatio), tadalafil (Adcirca), vardenafil	sildenafil citrate (Revatio), tadalafil (Adcirca), vardenafil
hydrochloride hydrate, lomitapide mesilate, venetoclax [during its	hydrochloride hydrate, lomitapide mesilate, venetoclax [during its
dose escalation phase for relapsed or refractory chronic	dose escalation phase for relapsed or refractory chronic
lymphocytic leukemia (including small lymphocytic lymphoma)],	lymphocytic leukemia (including small lymphocytic lymphoma)],
diazepam, clorazepate dipotassium, estazolam, flurazepam	diazepam, clorazepate dipotassium, estazolam, flurazepam
hydrochloride, triazolam, midazolam, voriconazole, apalutamide,	hydrochloride, triazolam, midazolam, voriconazole, apalutamide,
carbamazepine, phenytoin, fosphenytoin sodium hydrate,	carbamazepine, phenytoin, fosphenytoin sodium hydrate,
phenobarbital, mepenzolate bromide/phenobarbital, rifampicin, food	phenobarbital, mepenzolate bromide/phenobarbital, rifampicin,
containing St. John's Wort	enzalutamide, food containing St. John's Wort
10. INTERACTIONS	10. INTERACTIONS
10.1 Contraindications for Co-administration (Do not co-administer with	10.1 Contraindications for Co-administration (Do not co-administer with

the following.)	the following.)
DrugsSigns, symptoms, and treatmentMechanism/ris factorsPhenytoinAntiviral activity may disappear, and resistance may occur.The CYP3A4- inducing activity these drugs may lead to a decreas in the blood concentration of nirmatrelvir and ritonavir.	DrugsSigns, symptoms, and treatmentMechanism/risk factorsPhenytoin Fosphenytoin sodium hydrateAntiviral activity may disappear, and resistance may occur.The CYP3A4- inducing activity of these drugs may lead to a decrease in the blood concentration of nirmatrelvir and ritonavir.